
Targeted or site-specific drug delivery is one of the ultimate goals in controlled drug delivery. In prodrug design, targeting can in general be achieved by site directed drug delivery or site-specific drug bioactivation. With site directed drug delivery the bioreversible prodrug is selectively or primarily transported, as an intact prodrug, to the site of drug action. On the other hand, with site-specific bioactivation, the prodrug can be widely distributed all over the body, but undergoes bioactivation and exerts activity only at the desired site. This roundtable will provide attendees with an overview of the current progress and various challenges and opportunities using prodrugs in drug targeting.
Tycho Heimbach, Ph.D.
Pfizer Global Research and Development
Jarkko T. Rautio, Ph.D.
University of Kuopio
Improved Liver-targeting: Novel Cyclic Phosphate Prodrugs Activated by Cytochrome P450's
Mark Erion, Ph.D.
Metabasis
Tumor-targeted Anticancer Prodrugs
Tamara Minko, Ph.D.
Rutgers University
Contact Us | Feedback
© 2007 American Association of Pharmaceutical Scientists www.aapspharmaceutica.com